We are live on ! Find out more
GNOM icon

Global X Genomics & Biotechnology ETF

52 hedge funds and large institutions have $12.4M invested in Global X Genomics & Biotechnology ETF in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.1% less ownership

Funds ownership: 9.08%6.98% (-2.1%)

12% less funds holding

Funds holding: 5952 (-7)

34% less capital invested

Capital invested by funds: $18.7M → $12.4M (-$6.29M)

35% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 23

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $103K

Holders
52
Holders Change
-7
Holders Change %
-11.86%
% of All Funds
0.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
15
Reduced
23
Closed
11
Calls
Puts
$103K
Net Calls
-$103K
Net Calls Change
-$66K
Name Holding Trade Value Shares
Change
Change in
Stake
FTUS
1
Flow Traders U.S.
New York
$2.01M +$650K +20,515 +52%
LPL Financial
2
LPL Financial
California
$1.26M +$408K +12,892 +53%
Bank of America
3
Bank of America
North Carolina
$1.06M -$66.8K -2,111 -6%
Two Sigma Investments
4
Two Sigma Investments
New York
$956K +$205K +6,475 +30%
OAM
5
Oppenheimer Asset Management
New York
$756K +$53.1K +1,677 +8%
IWM
6
IHT Wealth Management
Illinois
$563K -$129K -4,064 -20%
UBS Group
7
UBS Group
Switzerland
$513K -$110K -3,465 -19%
IA
8
Insight Advisors
Pennsylvania
$503K +$153K +4,830 +48%
SWP
9
Stratos Wealth Partners
Ohio
$485K -$36.6K -1,157 -7%
OCM
10
One Capital Management
California
$442K -$2.6M -82,012 -86%
AA
11
Armis Advisers
Georgia
$432K -$792 -25 -0.2%
SWA
12
Sightline Wealth Advisors
Connecticut
$418K -$12.3K -387 -3%
Jane Street
13
Jane Street
New York
$270K -$884K -27,922 -78%
ACS
14
Archford Capital Strategies
Illinois
$230K -$48.2K -1,522 -18%
PAG
15
Private Advisor Group
New Jersey
$198K +$22.2K +700 +14%
SEI Investments
16
SEI Investments
Pennsylvania
$195K +$95.8K +3,026 +110%
CFD
17
Creative Financial Designs
Indiana
$188K +$82K +2,589 +87%
NA
18
NewEdge Advisors
Louisiana
$185K +$161K +5,100 +1,360%
Raymond James Financial
19
Raymond James Financial
Florida
$185K -$124K -3,924 -42%
CMMS
20
Comprehensive Money Management Services
Florida
$173K +$1.17K +37 +0.7%
SAM
21
Smartleaf Asset Management
Massachusetts
$164K +$36.5K +1,154 +31%
AI
22
Atria Investments
North Carolina
$156K +$16.4K +518 +13%
OPWM
23
Oxinas Partners Wealth Management
Indiana
$137K +$13.9K +438 +12%
CF
24
Centaurus Financial
California
$126K -$7.5K -237 -6%
HighTower Advisors
25
HighTower Advisors
Illinois
$121K -$6.74K -213 -6%

GNOM Hedge Fund Activity: Q2 2025 in Review

52 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q2 2025, worth a combined $12.4M — down 34% from $18.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GNOM and 5 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 15 added.

The largest buyer was Flow Traders U.S., adding an estimated $650K. The largest seller was One Capital Management, cutting an estimated $2.6M.

  • 52 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q2 2025, down from 59 in Q1 2025.
  • Funds reported $12.4M of Global X Genomics & Biotechnology ETF stock for Q2 2025, down 34% quarter-over-quarter.
  • 5 funds opened new Global X Genomics & Biotechnology ETF positions in Q2 2025 and 11 closed out, a net change of -6 holders.
  • The largest Global X Genomics & Biotechnology ETF buyer in Q2 2025 was Flow Traders U.S., an estimated $650K added.
  • The largest Global X Genomics & Biotechnology ETF seller in Q2 2025 was One Capital Management, an estimated $2.6M sold.

Based on aggregated 13F filings for Q2 2025.